Some great summaries here on this thread for Leslie’s interview with Dani from Proactive Investors. A recurring theme is safety, lack of toxicity & something that was repeated multiple times, COMBINATION therapy.
IMU pipeline includes multiple indications, albeit at earlier stages than their lead candidate HER-VAXX. Will we be seeing combination trials with T cell vaccines (ie Keytruda) which is still in ongoing trials to increase indications for Merck’s multi-billion dollar drug & B cell vaccines as an adjunct immunotherapy to increase immune response in cancer in the near future +/- chemotherapy? This is something I got as a possibility from the interview in regards to ‘beautiful combinations’, & purely IMO.
Aside from this, exceptionally pleased with the announcement that IMU will have 3 poster presentations at AACR & research published. That’s impressive. We will all get to read these once the embargo is lifted on presentations. GLTAH
Leslie Chong Interview 2, page-15
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
